This study aimed to investigate graft-versus-leukemia (GVL) of haploidentical donor (HID)
compared with HLA-matched sibling donor (MSD) for high-risk acute myeloid leukemia (H …

The effects of HLA-identical sibling donor (ISD) hematopoietic stem cell transplantation
(HSCT) on adults with intermediate-or high-risk acute myeloid leukemia (AML) in the first …

Allogeneic hematopoietic stem cell transplantation is the optimal care for patients with high-
risk or intermediate-acute myeloid leukemia. In patients lacking matched sibling donor …

Background Compared with HLA-matched sibling donor (MSD) transplant, the outcomes of
haploidentical donor (HID) transplant for refractory acute leukemia need to be further …

The outcomes of an historic comparison of 117 consecutive, high-risk, acute leukemia
patients undergoing hematopoietic stem cell transplantation (HSCT) from HLA-mismatched …

We compared the outcomes of unrelated donor (URD, n= 358) with human leukocyte
antigen (HLA)–matched sibling donor (MSD, n= 226) transplantations in patients with acute …

HLA-haploidentical hematopoietic cell transplantation (Haplo-HCT) using
posttransplantation cyclophosphamide (PT-Cy) has improved donor availability. However, a …

Approximately one-third of patients with an indication for hematopoietic cell transplantation
(HCT) have an HLA-matched related donor (MRD) available to them. For the remaining …

Primary refractory or relapsed acute myeloid leukemia is associated with a dismal
prognosis. Allogeneic stem cell transplantation is the only therapeutic option that offers …

Background Previous reports suggest a benefit associated with haploidentical donor
transplantation (HIDT) compared to matched sibling donor transplantation (MSDT) in certain …